



NORWAY

(12) Translation of
European patent specification

(11) NO/EP 3050882 B1

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61K 31/519 (2006.01)
A61P 3/10 (2006.01)
A61P 17/00 (2006.01)
A61P 19/02 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)
C07D 487/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.06.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.01.31
(86)	European Application Nr.	15195698.4
(86)	European Filing Date	2011.03.09
(87)	The European Application's Publication Date	2016.08.03
(30)	Priority	2010.03.10, US, 312588 P 2010.11.19, US, 415602 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(62)	Divided application	EP2545045, med inndato 2011.03.09
(73)	Proprietor	Incyte Holdings Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, US-USA
(72)	Inventor	HUANG, Taisheng, 522 Chariot Court, Wilmington, DE 19808, US-USA XUE, Chu-Biao, 307 Wellspring Court, Hockessin, DE 19707, US-USA WANG, Anlai, 102 Bunting Drive, Wilmington, DE 19808, US-USA YE, Hai Fen, 45 West Park Place, New ark, DE 19711, US-USA YAO, Wenqing, 748 Meadow bank Road, Kennett Square, PA 19348, US-USA RODGERS, James D., 2 Hillside Lane, Landenberg, PA 19350, US-USA SHEPARD, Stacey, 2200 C Inglew ood Road, Wilmington, DE 19803, US-USA WANG, Haisheng, 207 Hockessin Circle, Hockessin, DE 19707, US-USA SHAO, Lixin, 20 Presidential Drive, Apt C, Wilmington, DE 19807, US-USA LI, Hui-Yin, 161 Thompson Drive, Hockessin, DE 19707, US-USA LI, Qun, 10 Crompton Court, New ark, DE 19702, US-USA KONG, Linguan, 5 Fritze Court, Hockessin, DE 19707, US-USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge
(54)	Title	PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
(56)	Reference Cited:	WO-A1-2007/070514, WO-A1-2007/117494, US-A1- 2009 233 903, WO-A1-2012/068450, WO-A1-2010/039939

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse som er {1-{1-[3-fluor-2-(trifluormetyl)isonikotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitril eller et farmasøytisk akseptabelt salt derav, for anvendelse ved behandling av en sykdom valgt fra allograft-avstøtning og transplantat-mot-verts-sykdom.
5
2. Forbindelse eller salt for anvendelse ifølge krav 1, hvor saltet er {1-{1-[3-fluor-2-(trifluormetyl)isonikotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitril adipinsyresalt.
3. Forbindelse eller salt for anvendelse ifølge krav 1 eller 2, hvor sykdommen er allograft-avstøtning.
10
4. Forbindelse eller salt ifølge krav 1 eller 2, hvor sykdommen er transplantat-mot-verts-sykdom.
5. Anvendelse av forbindelse som er {1-{1-[3-fluor-2-(trifluormetyl)isonikotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitril, eller et farmasøytisk akseptabelt salt derav, for fremstilling av et medikament for behandling av en sykdom valgt fra allograft-avstøtning og transplant-mot-verts-sykdom.
15
6. Anvendelse ifølge krav 5, hvor saltet er {1-{1-[3-fluor-2-(trifluormetyl)isonikotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitril adipinsyresalt.
20
7. Anvendelse ifølge krav 5 eller 6, hvor sykdommen er allograft-avstøtning.
8. Anvendelse ifølge krav 5 eller 6, hvor sykdommen er transplantat-mot-vertssykdom.